**Evidence Table I-22. Adverse events in studies comparing fluid strategies for the prevention of contrast induced nephropathy and other outcomes.**

|  |  |
| --- | --- |
| **Author, Year** | **Adverse events** |
| Bader,2004[7](#_ENREF_7" \o "Bader, 2004 #2592) | NR  |
| Brar, 2014[9](#_ENREF_9) | Shortness of breath |
| Mueller, 2002[49](#_ENREF_49) | Vascular complications, 13 cases in the control group and 12 cases in the treatment group |
| Chen, 2008[14](#_ENREF_14) | Adverse events reported by CIN, non-CIN status; Many conditions listed have no known correlation with intervention. They include major bleeding, death secondary to stroke, mechanical ventilation, continuous veno-venous filtration |
| Cho, 2010[15](#_ENREF_15) | Other: in-house mortality; 0 in all arms  |
| Koc, 2012[31](#_ENREF_31) | No adverse reactions besides CIN |
| Kong, 2012[32](#_ENREF_32) | NR |
|  Krasuski, 2003[35](#_ENREF_35) | NR |
| Lawlor, 2007[37](#_ENREF_37) | Other: adverse side effects to NAC or placebo; no adverse side effects related to treatment with NAC or placebo were reported; Acute renal failure; No patients developed acute renal failure that required dialysis following their angiograms |
| Maioli, 2011[44](#_ENREF_44) | Other: Major bleeding, Arm1: 8 (5.3%), Arm2: 12 (8%), Arm3: 6 (4%), Stroke, 2 cases (1.3%) in each arm, |
| Manari, 2014[45](#_ENREF_45) | NR |
| Marron, 2007[48](#_ENREF_48) | NR |
| Trivedi, 2003[63](#_ENREF_63) | Other: adverse effects of saline hydration, (Amongst patients with contrast-induced renal failure, hospitalization was prolonged in 3 patients in the control group and 1 patient in the treatment group) |

CIN=contrast induced nephropathy; g/kg/day=gram per kilogram per day; NAC=N-acetylcysteine; NaCl=sodium chloride; NR=not reported